First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [31] Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP
    Lopez-Beltran, Antonio
    Gonzalez-Peramato, Pilar
    Sanz-Ortega, Julian
    Cuadra, Juan Daniel Prieto
    Trias, Isabel
    Barona, Rafael J. Luque
    Semidey, Maria Eugenia
    Maroto, Pablo
    Algaba, Ferran
    REVISTA ESPANOLA DE PATOLOGIA, 2023, 56 (04): : 261 - 270
  • [32] Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis
    Monteiro, Fernando Sabino Marques
    Soares, Andrey
    Mollica, Veronica
    Leite, Caio Abner
    Carneiro, Andre Paterno Castello Dias
    Rizzo, Alessandro
    Bourlon, Maria T.
    Sasse, Andre Deeke
    Santoni, Matteo
    Gupta, Shilpa
    Massari, Francesco
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [33] PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
    Stenehjem, David D.
    Tran, Dao
    Nkrumah, Michael A.
    Gupta, Shilpa
    ONCOTARGETS AND THERAPY, 2018, 11 : 5973 - 5989
  • [34] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
  • [35] First-line treatment of metastatic urothelial carcinoma Update immuno-oncology
    Zacharis, A.
    Gruellich, C.
    UROLOGE, 2020, 59 (07): : 797 - 803
  • [36] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [37] Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials
    Shi, Yuanchao
    Duan, Jingwei
    Guan, Quanlin
    Xue, Penglong
    Zheng, Ya
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 84
  • [38] A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Hanna, Kirollos S.
    PHARMACOTHERAPY, 2017, 37 (11): : 1391 - 1405
  • [39] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Isla, Dolores
    Lopez-Brea, Marta
    Espinosa, Maria
    Arrabal, Natalia
    Perez-Parente, Diego
    Carcedo, David
    Bernabe-Caro, Reyes
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [40] PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
    Gevaert, Thomas
    Cimadamore, Alessia
    Montironi, Rodolfo
    Eckstein, Markus
    CURRENT DRUG TARGETS, 2021, 22 (02) : 162 - 170
12345